Onyx Pharmaceuticals News
Onyx Pharmaceuticals (Nasdaq:ONXX) has been reiterated by TheStreet Ratings as a hold with a ratings score of C-
ONYX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VoMay 23
TheStreet Ratings group highlights 5 stocks pushing the drugs industry higher today.
Onyx Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 10:30 AM
Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology AssociationMarketwired May 21
Onyx Pharmaceuticals, Inc. today announced the upcoming presentation of data highlighting Kyprolis® for Injection, a second-generation proteasome inhibitor, and oprozomib, an oral proteasome inhibitor ...
Onyx Pharmaceuticals was a leading decliner within the drugs industry, falling $1.43 (-1.5%) to $92.91 on average volume
A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesMay 16
InPlay: Onyx Pharma announces data presentations at 49th American Society of Clinical Oncology Annual MeetingMay 15
Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual MeetingMarketwired May 15
Onyx Pharmaceuticals, Inc. today announced the upcoming presentations of data highlighting Nexavar® tablets, Kyprolis® for Injection, and Stivarga® tablets across a range of cancers. These presentations ...